Neurodegenerative movement disorders present profound diagnostic challenges worldwide, especially when clinicians must distinguish idiopathic parkinsonism from atypical variants. A recent landmark study evaluated whether whole-blood mitochondrial DNA copy number and telomere length can serve as differential peripheral biomarkers. Clinicians frequently encounter diagnostic overlap between early Parkinson's disease and multiple system atrophy because both disorders display similar motor features. However, their clinical trajectories and therapeutic responses differ substantially. By evaluating peripheral markers of cellular aging, investigators identified distinct mitochondrial profiles between these two conditions. Consequently, these findings offer a practical, blood-based diagnostic framework for clinical neurology.

The Diagnostic Dilemma in α-Synucleinopathies

Clinicians regularly confront formidable hurdles when evaluating parkinsonian phenotypes in neurological clinics. Parkinson's disease represents the most common neurodegenerative movement disorder in elderly populations. In contrast, multiple system atrophy is an aggressive, rapidly progressing atypical parkinsonian disorder. Both diseases belong to the α-synucleinopathy family, featuring pathologic aggregates of α-synuclein protein across various central nervous system pathways. While Parkinson's disease selectively targets dopaminergic neurons in the substantia nigra, multiple system atrophy drives widespread oligodendroglial cytoplasmic inclusions. Consequently, multiple system atrophy causes early autonomic failure, cerebellar ataxia, and accelerated functional decline.

During early symptomatic stages, the clinical presentations overlap remarkably. Patients routinely report tremor, muscular rigidity, bradykinesia, and subtle postural instability in both conditions. Standard clinical examinations cannot reliably separate these conditions before atypical red flags appear. Furthermore, patients with multiple system atrophy typically display poor or short-lived responses to dopaminergic medications. Misdiagnosis occurs in up to twenty percent of clinicopathological cohorts. Therefore, movement disorder specialists urgently require objective, non-invasive peripheral biomarkers. Reliable blood tests could transform clinical prognostication, expedite multidisciplinary interventions, and improve trial enrollment.

Evaluating Mitochondrial DNA Copy Number in Peripheral Blood

To discover accessible peripheral biomarkers, investigators examined whole-blood mitochondrial DNA copy number alongside telomere length across southern Italian cohorts. Mitochondria perform essential physiological tasks, producing cellular ATP through oxidative phosphorylation while regulating apoptotic signaling. Central neurons depend heavily on mitochondrial integrity because synaptic transmission requires continuous metabolic energy. However, mitochondrial DNA remains uniquely susceptible to oxidative injury due to its lack of protective histones. When mitochondrial damage accumulates, cells actively modulate their mitochondrial genome abundance to compensate for cellular stress.

The clinical study evaluated blood samples from 58 Parkinson's disease patients, 35 multiple system atrophy patients, and 62 healthy controls. Specifically, researchers used quantitative real-time PCR assays targeting the mitochondrially encoded NADH dehydrogenase 1 gene. They normalized these measurements against the nuclear β-actin reference gene. After adjusting for age and sex through multivariable linear regression, statistical analyses showed significant group differences. The circulating mitochondrial DNA copy number distinguished Parkinson's disease from multiple system atrophy with high statistical fidelity. Thus, peripheral mitochondrial copy levels capture distinct disease-specific pathophysiological mechanisms.

Contrasting Telomere Length and mtDNA Dynamics

In addition to mitochondrial biology, telomere maintenance represents another primary hallmark of organismal aging. Telomeres consist of repetitive hexanucleotide sequences capping the terminal regions of chromosomes. They progressively shorten during cellular replication and periods of heightened oxidative stress. Because neurodegenerative disorders accelerate cellular senescence, researchers frequently examine whether telomere attrition reflects specific disease states. However, the study uncovered striking distinctions between these two molecular markers.

While mitochondrial DNA copy number differentiated multiple system atrophy from Parkinson's disease, leukocyte telomere length showed no diagnostic divergence between groups. Both patient cohorts displayed age-adjusted alterations in telomere length relative to healthy individuals. Nevertheless, telomere measurements could not distinguish the specific clinical disorders. Telomere attrition appears to reflect generalized biological senescence, cumulative inflammation, and systemic neurodegenerative stress. Therefore, telomere length behaves as a non-specific indicator of aging rather than a disorder-specific molecular signature. By directly comparing both markers within the same cohort, the researchers established the superior diagnostic value of mitochondrial copy quantification. Consequently, mitochondrial metrics offer targeted mechanistic insight that broad senescence clocks cannot provide.

Mechanisms Linking Mitochondrial Depletion to MSA Pathology

The biological pathways underlying divergent mitochondrial copy numbers provide crucial insights into α-synucleinopathy pathogenesis. In Parkinson's disease, mitochondrial impairment has long been recognized as a central pathogenic feature. Environmental toxins and genetic mutations in parkin or PINK1 directly disrupt mitophagy and electron transport. However, multiple system atrophy involves a distinct oligodendroglial pathology that produces profound metabolic exhaustion.

Oligodendrocytes maintain extensive myelin sheaths and provide metabolic sustenance to vulnerable axonal projections. When α-synuclein accumulates as glial cytoplasmic inclusions, oligodendrocytes experience severe mitochondrial dysfunction and energetic collapse. Furthermore, defective mitochondrial biogenesis and impaired quality control deplete functional mitochondrial genomes in circulating immune cells. Because peripheral leukocytes reflect systemic inflammatory and metabolic stress, whole-blood assays capture these alterations accurately. Consequently, multiple system atrophy patients exhibit marked alterations in peripheral mitochondrial genome abundance. This systemic metabolic failure explains why multiple system atrophy follows an aggressive course compared to classical Lewy body disease. Understanding these distinct pathways clarifies why circulating mitochondrial markers reflect unique disease pathology.

Translational Potential and Clinical Validation

The clinical implications of a validated blood-based biomarker are immense for clinical neurology and geriatric medicine. Currently, separating multiple system atrophy from Parkinson's disease relies on prolonged longitudinal observation, autonomic testing, and advanced neuroimaging. For example, clinicians utilize magnetic resonance imaging or positron emission tomography to identify characteristic atrophy patterns. Unfortunately, structural imaging signs, such as cerebellar atrophy or the putaminal rim sign, emerge late in disease progression.

Moreover, specialized neuroimaging remains expensive, technically demanding, and unavailable in many resource-limited healthcare environments. In contrast, measuring mitochondrial DNA copy number requires only routine peripheral venipuncture and standard quantitative PCR equipment. Most hospital laboratories already possess the diagnostic infrastructure necessary to run these quantitative assays. If subsequent multi-center studies validate these findings across larger, multi-ethnic patient populations, clinicians can integrate blood-based mitochondrial screening into everyday diagnostic workflows. Early diagnostic accuracy improves patient education and prevents ineffective drug escalation. Additionally, objective biological stratification will help clinical trials recruit uniform cohorts for targeted neuroprotective therapies. Ultimately, this accessible blood test could significantly accelerate translational discovery across movement disorders.

Frequently Asked Questions

How does mitochondrial DNA copy number differ between PD and MSA?

Whole-blood mitochondrial DNA copy number shows distinct alterations between these two disorders. Although both conditions share common clinical signs, patients with multiple system atrophy exhibit pronounced differences in mitochondrial DNA content compared to Parkinson's disease. Consequently, this circulating genetic marker effectively separates these two clinical entities within standardized diagnostic cohorts.

Why did telomere length fail to differentiate the two disorders?

Telomere length reflects cumulative biological senescence across tissues rather than pathology localized to specific neuronal pathways. Because both Parkinson's disease and multiple system atrophy involve shared neurodegenerative cascades and cellular aging pathways, telomere attrition occurs indiscriminately. Therefore, telomere measurement captures broad physiological aging instead of disease-specific biochemical mechanisms in neurodegenerative disorders.

Can this blood test replace conventional neuroimaging in clinics?

Circulating mitochondrial biomarkers cannot yet replace magnetic resonance imaging or nuclear scintigraphy in routine clinical care. However, quantitative measurement provides an objective, minimally invasive adjunct to support early diagnosis. Clinicians can integrate this assay with structural imaging and autonomic evaluation to enhance diagnostic accuracy when distinguishing challenging movement disorders.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

1. Gagliardi M et al. Preliminary insights into whole-blood mitochondrial DNA copy number and telomere length in Parkinson's disease and multiple system atrophy. J Neurol. 2026 Sep 29. doi: 10.1007/s00415-026-14172-7. PMID: 42809157.
2. Pyle A, et al. Reduced mitochondrial DNA copy number in peripheral blood of Parkinson's disease patients. Neurobiol Aging. 2016;38:216.e7-216.e10.
3. Fani L, et al. Leukocyte telomere length and the risk of neurodegenerative diseases: A prospective cohort study from the UK Biobank. Alzheimers Dement. 2024;20(3):1825-1834.